Compare Novo Nordisk A/S (NVO) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Vanguard Short Term Corporate Bond ETF — how do they compare? Novo Nordisk A/S trades at $49.32 (market cap $220.53B), while Vanguard Short Term Corporate Bond ETF trades at $78.58. The key difference: Novo Nordisk A/S pays a 3.63% dividend while Vanguard Short Term Corporate Bond ETF pays none, and Novo Nordisk A/S is trading nearer its 52-week high, Vanguard Short Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| NVO | VCSH | |
|---|---|---|
Market Cap | $220.53B | — |
Sector | Health | Fixed Income |
52-Week High | $71.70 | $80.20 |
52-Week Low | $35.29 | $78.45 |
Enterprise Value | $239.49B | — |
Dividend Yield | 3.63% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →
